Complement activation in Glioblastoma Multiforme pathophysiology: Evidence from serum levels and presence of complement activation products in tumor tissue

Journal of Neuroimmunology

Volumn 278, Issue , 2015, Pages 271-276

  Bouwens, T A M ^a   Trouw, L A ^b   Veerhuis, R ^c   Dirven, C M F ^a   Lamfers, M L M ^a   Al Khawaja, H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

C1q; Complement system; Factor B; Glial tumor; Glioblastoma multiforme; Mannose binding lectin (MBL)

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT MEMBRANE ATTACK COMPLEX; MANNOSE BINDING LECTIN;

ADULT; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MANNOSE BINDING LECTIN DEFICIENCY; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; BLOOD; BRAIN TUMOR; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SURVIVAL;

ADULT; BRAIN NEOPLASMS; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT FACTOR B; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 84920921429     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.11.016     Document Type: Article

References (40)

1. Adamson C., Kanu O.O., Mehta A.I., Di C., Lin N., Mattox A.K., Bigner D.D. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin. Investig. Drugs 2009, 18:1061-1083.
2. Andrades J.A., Nimni M.E., Becerra J., Eisenstein R., Davis M., Sorgente N. Complement proteins are present in developing endochondral bone and may mediate cartilage cell death and vascularization. Exp. Cell Res. 1996, 227:208-213.
3. Baccarelli A., Hou L., Chen J., Lissowska J., El-Omar E.M., Grillo P., Giacomini S.M., Yaeger M., Bernig T., Zatonski W., Fraumeni J.F., Chanock S.J., Chow W.H. Mannose-binding lectin-2 genetic variation and stomach cancer risk. Int. J. Cancer 2006, 119:1970-1975.
4. Bach J.P., Deuster O., Balzer-Geldsetzer M., Meyer B., Dodel R., Bacher M. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer 2009, 115:2031-2040.
5. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
6. Beurskens F.J., Lindorfer M.A., Farooqui M., Beum P.V., Engelberts P., Mackus W.J., Parren P.W., Wiestner A., Taylor R.P. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J. Immunol. 2012, 188:3532-3541.
7. Cai Y., Yang Q., Tang Y., Zhang M., Liu H., Zhang G., Deng Q., Huang J., Gao Z., Zhou B., Feng C.G., Chen X. Increased complement C1q level marks active disease in human tuberculosis. PLoS One 2014, 9:e92340.
8. Castellano G., Woltman A.M., Nauta A.J., Roos A., Trouw L.A., Seelen M.A., Schena F.P., Daha M.R., van Kooten C. Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood 2004, 103:3813-3820.
9. Gullstrand B., Martensson U., Sturfelt G., Bengtsson A.A., Truedsson L. Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin. Exp. Immunol. 2009, 156:303-311.
10. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
11. Hong Q., Sze C.I., Lin S.R., Lee M.H., He R.Y., Schultz L., Chang J.Y., Chen S.J., Boackle R.J., Hsu L.J., Chang N.S. Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One 2009, 4:e5755.
12. Jensen R.L. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J. Neuro-Oncol. 2009, 92:317-335.
13. Kang Y.H., Urban B.C., Sim R.B., Kishore U. Human complement factor H modulates C1q-mediated phagocytosis of apoptotic cells. Immunobiology 2012, 217:455-464.
14. Kanu O.O., Mehta A., Di C., Lin N., Bortoff K., Bigner D.D., Yan H., Adamson D.C. Glioblastoma multiforme: a review of therapeutic targets. Expert Opin. Ther. Targets 2009, 13:701-718.
15. Li A., Walling J., Ahn S., Kotliarov Y., Su Q., Quezado M., Oberholtzer J.C., Park J., Zenklusen J.C., Fine H.A. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res. 2009, 69:2091-2099.
16. Madsen H.O., Garred P., Kurtzhals J.A., Lamm L.U., Ryder L.P., Thiel S., Svejgaard A. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 1994, 40:37-44.
17. Markiewski M.M., Lambris J.D. Unwelcome complement. Cancer Res. 2009, 69:6367-6370.
18. Markiewski M.M., Lambris J.D. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 2009, 30:286-292.
19. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., Coukos G., Lambris J.D. Modulation of the antitumor immune response by complement. Nat. Immunol. 2008, 9:1225-1235.
20. Martin M., Leffler J., Blom A.M. Annexin A2 and A5 serve as new ligands for C1q on apoptotic cells. J. Biol. Chem. 2012, 287:33733-33744.
21. Mead R., Jack D., Pembrey M., Tyfield L., Turner M. Mannose-binding lectin alleles in a prospectively recruited UK population. The ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Lancet 1997, 349:1669-1670.
22. Minchinton R.M., Dean M.M., Clark T.R., Heatley S., Mullighan C.G. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an Australian blood donor population. Scand. J. Immunol. 2002, 56:630-641.
23. Mook-Kanamori B.B., Brouwer M.C., Geldhoff M., Ende A.V., van deBeek D. Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis. J. Infect. 2014.
24. Nauta A.J., Trouw L.A., Daha M.R., Tijsma O., Nieuwland R., Schwaeble W.J., Gingras A.R., Mantovani A., Hack E.C., Roos A. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur. J. Immunol. 2002, 32:1726-1736.
25. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
26. Rong Y., Jin D., Hou C., Hu J., Wu W., Ni X., Wang D., Lou W. Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2. BMC Gastroenterol. 2010, 10:68.
27. Roos A., Bouwman L.H., van Gijlswijk-Janssen D.J., Faber-Krol M.C., Stahl G.L., Daha M.R. Human IgA activates the complement system via the mannan-binding lectin pathway. J. Immunol. 2001, 167:2861-2868.
28. Rutkowski M.J., Sughrue M.E., Kane A.J., Mills S.A., Parsa A.T. Cancer and the complement cascade. Mol. Cancer Res. 2010, 8:1453-1465.
29. Skattum L., van Deuren M., van der Poll T., Truedsson L. Complement deficiency states and associated infections. Mol. Immunol. 2011, 48:1643-1655.
30. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., Chan C., Parren P.W., Hack C.E., Dechant M., Valerius T., van de Winkel J.G., Glennie M.J. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104:1793-1800.
31. Trouw L.A., Blom A.M., Gasque P. Role of complement and complement regulators in the removal of apoptotic cells. Mol. Immunol. 2008, 45:1199-1207.
32. Turner M.W. The role of mannose-binding lectin in health and disease. Mol. Immunol. 2003, 40:423-429.
33. Veerhuis R., Janssen I., De Groot C.J., Van Muiswinkel F.L., Hack C.E., Eikelenboom P. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Exp. Neurol. 1999, 160:289-299.
34. Veerhuis R., Janssen I., Hack C.E., Eikelenboom P. Early complement components in Alzheimer's disease brains. Acta Neuropathol. 1996, 91:53-60.
35. Veerhuis R., Nielsen H.M., Tenner A.J. Complement in the brain. Mol. Immunol. 2011, 48:1592-1603.
36. Wiemann B., Starnes C.O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol. Ther. 1994, 64:529-564.
37. Worthley D.L., Bardy P.G., Gordon D.L., Mullighan C.G. Mannose-binding lectin and maladies of the bowel and liver. World J. Gastroenterol. 2006, 12:6420-6428.
38. Xu W., Berger S.P., Trouw L.A., de Boer H.C., Schlagwein N., Mutsaers C., Daha M.R., van Kooten C. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J. Immunol. 2008, 180:7613-7621.
39. Yin W., Ghebrehiwet B., Weksler B., Peerschke E.I. Classical pathway complement activation on human endothelial cells. Mol. Immunol. 2007, 44:2228-2234.
40. Ytting H., Jensenius J.C., Christensen I.J., Thiel S., Nielsen H.J. Increased activity of the mannan-binding lectin complement activation pathway in patients with colorectal cancer. Scand. J. Gastroenterol. 2004, 39:674-679.